复方苦参在晚期非小细胞肺癌化疗中辅助作用的临床研究.docVIP

复方苦参在晚期非小细胞肺癌化疗中辅助作用的临床研究 　　摘要：目的 研究评价非小细胞肺癌晚期患者化疗同时应用复方苦参注射液的作用和效果。方法 将2009年1月～2014年1月我科收治的非小细胞肺癌晚期86例患者随机分成对照组和试验组各43例，比较两组临床受益情况、生活质量、疼痛缓解程度和不良反应发生情况。结果 对照组临床受益率为30.5%、试验组为38.2%、差异不具有统计学意义（P0.05）；试验组疼痛缓解率为85.4%，对照组只有67.3%、差异存在统计学意义（P0.05）；对照组在不良反应发生率方面为78.5%，试验组只有33.1%，差异具有统计意义（P0.01）。结论 非小细胞性肺癌晚期患者进行化疗治疗的同时配合使用复方苦参注射液能够使患者的痛苦降低，不良反应会得到减少，使患者的生活质量得到提高。 　　关键词：非小细胞性肺癌；复方苦参注射液；化疗 　　Clinical Study of Compound Matrine in Chemotherapy of Advanced Non Small Cell Lung Cancer 　　HAN Bin 　　（Xinzhou Municipal Peoples Hospital，Xinzhou 034000，Shanxi，China） 　　Abstract：Objective Study on evaluation of chemotherapy in patients with advanced non-small cell lung cancer and the application of compound matrin injection and the effect. Methods 86 cases with non small cell lung cancer diagnosed in our hospital from January 2009 to January 2014 were randomly divided into control group and 43 cases of the test group， compared two groups of clinical benefit， quality of life， pain relief and adverse reactions.Results Clinical benefit rate for the control group 30.5%， the test group 38.2%， the difference was not statistically significant clinical benefit rate （P0.05）； the control group rates of pain relief for 67.3%， the test group pain relief was 85.4%， there was a statistically significant difference （P0.05）； the control group incidence of adverse reactions was 78.5%， the test group incidence of adverse reactions was 33.1%， there was a statistically significant difference （P0.01）.Conclusion Chemotherapy of patients with advanced non-small cell lung cancer treatment and the application of compound matrin injection can relieve pain in patients with reduced pain， reduce side effects and improve the patients quality of life. 　　Key words：Non-small cell lung cancer； Compound matrin injection； Chemotherapy； 　　肺癌中约有80%为非小细胞性肺癌，而其中约有60%为晚期患者[1]。化疗治疗是晚期患者最常用的治疗手段。但常因药物的毒性反应而中途放弃，复方苦参注射液是由苦参、白土茯苓、山慈菇、五灵脂、何首乌等中药精制而成的纯中药抗癌制剂，具有抗癌、增强免疫、止血及止痛等作用。2009年1月～2014年1月，我院采用复方苦参注射液辅助治疗晚期非小细胞肺癌（NSCLC）患者86